US Department of Defense grant programs advance

Highlights

- Flavocide® wearable device project (**Grant 1**) is progressing through device engineering and formulation development
- Early small-cage entomology trials have demonstrated evidence of mosquito mortality, indicating that the emanator concept is performing as expected
- Qcide® indoor spray project (**Grant 2**) pending initiation following lifting of the US Government shutdown and finalisation of agreements with US partners
- Both projects reaffirm Bio-Gene's alignment with the US Deployed Warfighter Protection (**DWFP**) program's objective to develop novel solutions that protect military and civilian populations from insect-borne disease threats

Bio-Gene Technology Limited (ASX:BGT, Bio-Gene or the Company), an Australian company developing the next generation of novel insecticides derived from nature, is pleased to provide an update on the two US Department of Defense (**DoD**) programs announced by the Company on 29 January 2025.

These two programs are being funded by competitive grants totalling A$3.0M (US$1.9M) over a three-year period and awarded to Bio-Gene under the DoD *Deployed Warfighter Protection* (**DWFP***)* program.

Grant 1 – Flavocide wearable device project

The program to develop a wearable device containing Flavocide, for protection against flying insect vectors, is well underway and progressing in accordance with the original project plan. Activities to date have focused on device engineering and formulation development, which is being carried out by GearJump Technologies, LLC. in collaboration with USDA and US military research institutions[1].

With this foundation in place, the initial entomological testing phase has also been undertaken. The performance of the Flavocide containing prototype devices against target mosquito species are being investigated in association with CMAVE-ARS-USDA. Early small-cage entomology trials have demonstrated evidence of mosquito mortality, indicating that the emanator concept is performing as expected at this stage.

Grant 2 – Qcide indoor residual spray project

The Qcide project, which aims to develop a residual spray formulation for indoor control of bed bugs, other crawling pests and houseflies, is pending initiation following the lifting of the recent US

[1] U.S. Army Combat Capabilities Development Command, Aberdeen Proving Ground, Maryland, USA (DEVCOM), Center for Medical, Agricultural and Veterinary Entomology, Agricultural Research Service, U.S. Department of Agriculture, Gainesville, Florida, USA (CMAVE-ARS-USDA), and Walter Reed Army Institute of Research – Armed Forces Research Institute of Medical Sciences, Bangkok (WRAIR AFRIMS)

Government shutdown and finalisation of contracts with US partners. Workstreams are being established to enable laboratory studies with prototype formulations to begin, initially with testing of prototype formulations against houseflies by CMAVE-ARS-USDA early in 2026.

Tim Grogan, Bio-Gene Technology's Managing Director & CEO said: *"These two projects highlight the global recognition of Bio-Gene's novel technology platform. The Flavocide wearable device project is already progressing through its development phases, including initial testing against mosquitoes. The Qcide spray project is advancing, and together these programs showcase the breadth of applications for our natural product-derived insecticides. With the incidence of insect-borne diseases rising worldwide, these DWFP projects represent an important opportunity to deliver safer, more effective solutions for both military and civilian use."*

***Dr Noel Elman, GearJump Technologies' CEO** added:* "*We are pleased to be working with Bio-Gene and our research collaborators to advance our novel wearable device platform incorporating Flavocide. While the program remains at an early stage, initial experiments and trials are helping assess performance and efficacy, and we look forward to continuing this work in a systematic and rigorous manner."*

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the globalchallenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au